Allopurinol/lesinurad

Drug Profile

Allopurinol/lesinurad

Alternative Names: DUZALLO; Lesinurad allopurinol FDC; Lesinurad/allopurinol; lesinurad/allopurinol 200/300 FDC; RDEA-594/allopurinol; Zurampic/Allopurinol FDC

Latest Information Update: 01 Jul 2017

Price : $50

At a glance

  • Originator Ardea Biosciences
  • Class Acetic acids; Antigouts; Cyclopropanes; Naphthalenes; Purines; Small molecules; Sulfides; Triazoles; Urologics
  • Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Gout

Most Recent Events

  • 04 Jan 2017 The US FDA accepts NDA for Allopurinol/lesinurad for Gout for review
  • 01 Oct 2016 Preregistration for Gout in USA (PO)
  • 01 Aug 2016 Ardea Biosciences initiates a bioequivalence phase I trial in Healthy volunteers in USA (PO) (NCT02888054)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top